Siemens Healthineers tapped NuVasive as a partner in minimally invasive spine surgery, integrating surgical automation platforms with 3D imaging.

Agilent’s PD-L1 assay was expanded in Europe to help guide first-line Keytruda treatment in urothelial carcinoma.

Credence MedSystems received a shot of $12.8 million in financing through a series B round.

Sensyne Health plans to go public with a £60 million listing ($77 million) on the London Stock Exchange on Aug. 17.

Merck and HitGen upsized their licensing agreement to a full discovery collaboration, screening DNA-encoded libraries of billions of small molecules.

Pfizer tapped Antares Pharma to develop a rescue pen for an undisclosed drug, shortly after investing $465 million in a new sterile injectables plant.

Evidation Health raised $30 million in financing, alongside the launch of a platform that digests sensor and behavioral data from real-world settings.

Castle Biosciences’ DecisionDx test improved predictions of melanoma recurrence risk by measuring 31 tumor genes compared to staging alone.